Developer docs
API playgroundTry for free, no card

Search company profiles

Structure Therapeutics

Full company profile

uuid00022k3

Namestring
Structure Therapeutics
Legal namestring
Structure Therapeutics, Inc.
Websiteurl
structuretx.com
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for chronic metabolic and cardiopulmonary diseases, with an initial focus on obesity. The company was founded in 2016 and is headquartered in South San Francisco, California, with a research and development center in Shanghai, China; it is publicly listed on NASDAQ under the ticker GPCR. Its core technology is a proprietary structure-based drug design platform that combines G-protein-coupled receptor (GPCR) structural biology, computational chemistry, and data science to design oral small molecules against the largest family of drug targets across multiple disease areas.

The company's pipeline is anchored by aleniglipron (also known as GSBR-1290), an oral small molecule GLP-1 receptor agonist that demonstrated up to 16.3% placebo-adjusted weight loss in the Phase 2 ACCESS II trial at 44 weeks with the 180mg dose and an overall discontinuation rate of 10.4%. Phase 3 initiation is planned for Q3 2026 with potential FDA approval targeted by 2029. The pipeline also includes ACCG-2671, an oral small molecule dual amylin and calcitonin receptor agonist in Phase 1; ACCG-3535, a preclinical dual amylin/calcitonin receptor agonist; and earlier-stage GIPR, GCGR, and GLP-1RA + Amylin combination programs. The platform was co-developed within Schrödinger's ecosystem, which retains approximately 6% equity in Structure.

Structure Therapeutics is pre-revenue and currently monetizes only through a non-exclusive patent licensing agreement with Roche/Genentech (CT-996 program) worth $100 million upfront plus low-single-digit royalties. Future revenue is expected to come from the sale of prescription oral obesity and metabolic disease medications upon regulatory approval, distributed through standard pharmaceutical wholesale and specialty pharmacy channels, targeting a global obesity population of more than 800 million patients and a total addressable market exceeding $100 billion. The company carries $1.4–1.5 billion in cash and investments as of early 2026 following a $747.5 million upsized public offering in December 2025, providing runway through 2028.

Short descriptiontext

Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for chronic metabolic and cardiopulmonary diseases, anchored by its GLP-1 agonist aleniglipron (Phase 2) for obesity and built on a structure-based drug design platform targeting GPCRs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oral small molecule therapeutics, GPCR drug discovery, obesity treatment pipeline, structure-based drug design, metabolic disease medicines
Industry1 code
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Obesity Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Structure Therapeutics is a pre-revenue clinical-stage biopharmaceutical company. Once products receive regulatory approval, the company plans to generate revenue through the sale of prescription medications, initially targeting the obesity and metabolic disease markets with oral small molecule GLP-1 and amylin receptor agonist therapeutics.

structuretx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Aleniglipron
Description

Oral small molecule GLP-1 receptor agonist for obesity treatment, currently in Phase 2 clinical trials showing up to 16.2% weight loss.

structuretx.com
+3 more records
Core offering1 text field

Structure Therapeutics is a clinical-stage biopharmaceutical company that develops oral small molecule therapeutics targeting G-protein-coupled receptors (GPCRs) for chronic metabolic and cardiopulmonary diseases, with an initial focus on obesity. The company leverages a proprietary structure-based drug design platform to create oral, non-peptide alternatives to injectable biologic and peptide therapies, addressing scalability, cost, and administration challenges of current treatments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Up to 16.3% placebo-adjusted weight loss at 44 weeks with aleniglipron 180mg dose in Phase 2 ACCESS II trial
+4 more records
Product overview1 text field

Structure Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of oral small molecule therapeutics for chronic metabolic and cardiopulmonary diseases, with an initial focus on obesity. The company's portfolio includes Aleniglipron (GSBR-1290), a GLP-1 receptor agonist in Phase 2 development showing up to 16.3% weight loss; ACCG-2671, a dual amylin and calcitonin receptor agonist in Phase 1; and ACCG-3535, a preclinical dual amylin/calcitonin receptor agonist. These candidates are designed as oral alternatives to injectable biologic and peptide therapies, leveraging the company's structure-based drug design platform targeting GPCRs to improve scalability and patient accessibility.

Product and service6 records
1Aleniglipron (GSBR-1290)
CategoryMetabolic (Obesity) - Phase 2
Description

An oral small molecule GLP-1 receptor agonist (GLP-1RA) for obesity treatment. Demonstrated up to 16.3% placebo-adjusted weight loss in Phase 2b ACCESS trials and positioned as a potential best-in-class oral GLP-1 therapy.

2ACCG-2671
CategoryMetabolic (Obesity) - Phase 1
Description

An oral small molecule dual amylin and calcitonin receptor agonist (DACRA) for obesity treatment. Currently in Phase 1 clinical study evaluating safety, tolerability, and pharmacokinetics in healthy volunteers and individuals with obesity.

3ACCG-3535
CategoryMetabolic (Obesity) - Preclinical / IND-Enabling
Description

A novel oral small molecule dual amylin and calcitonin receptor agonist for obesity treatment, in preclinical development stage.

4GIPR Program
CategoryMetabolic (Obesity) - Discovery
Description

Discovery-stage oral small molecule program targeting the GIP receptor for obesity and metabolic disease treatment.

5GCGR Program
CategoryMetabolic (Obesity) - Discovery
Description

Discovery-stage oral small molecule program targeting the glucagon receptor for obesity and metabolic disease treatment.

6GLP-1RA + Amylin Combination
CategoryMetabolic (Obesity) - IND-Enabling
Description

Combination therapy program combining an oral GLP-1 receptor agonist with an amylin receptor agonist for obesity treatment, in IND-enabling development.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-01-05
Description

Structure Therapeutics licensed patents to Roche for CT-996 (oral GLP-1 drug acquired through Carmot Therapeutics for $2.7 billion) in a deal worth $100 million upfront plus additional low-single-digit royalties on future net sales. The agreement protects Roche from potential patent infringement claims related to the drug, with Leerink Partners analysts noting this validates Structure's IP position in the oral GLP-1 space.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Structure Therapeutics was co-founded as part of Schrödinger's ecosystem of co-founded companies. Schrödinger holds approximately 6% equity in Structure and highlighted the company's Phase 2b data as a key milestone in its 2025 business update. Structure's structure-based drug discovery platform benefits from Schrödinger's computational molecular discovery capabilities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Terns Pharmaceuticals is a clinical-stage biotech developing TERN-601, an oral small molecule GLP-1 receptor agonist for obesity. Terns is one of the closest direct competitors to Structure's aleniglipron, targeting the same oral small molecule GLP-1 niche with similar patient access and scalability advantages over injectables.

TypeBroad incumbent
Description

Eli Lilly is the dominant incumbent in the GLP-1 obesity market with orforglipron (oral small molecule GLP-1 in late-stage trials) and retatrutide (28.3% weight loss in Phase 3). Lilly's massive commercial infrastructure, manufacturing scale, and capital make it Structure's most significant competitive threat and benchmark for oral GLP-1 efficacy.

TypeBroad incumbent
Description

Roche/Genentech acquired Carmot Therapeutics for $2.7B to access CT-996, an oral small molecule GLP-1, and subsequently licensed Structure's GLP-1 patents for $100M upfront. Roche is both a strategic counterparty and a competitive oral GLP-1 developer, making it a uniquely adjacent peer.

TypeBroad incumbent
Description

Novo Nordisk pioneered the GLP-1 category with semaglutide (Wegovy/Ozempic) and is advancing oral semaglutide formulations. As the established market leader with deep physician relationships, payer contracts, and global manufacturing, Novo represents both the incumbent benchmark and the most direct threat to Structure's oral obesity positioning.

TypeDirect peer
Description

Viking Therapeutics is a clinical-stage obesity-focused biotech with VK2735 (dual GLP-1/GIP injectable) showing strong weight loss in trials. While Viking's lead is injectable versus Structure's oral approach, both are mid-cap biotechs pursuing differentiated next-generation obesity therapeutics with similar competitive dynamics.

TypeEmerging player
Description

Metsera was an emerging obesity biotech (recently acquired by Pfizer for ~$10B) developing next-generation injectable and oral peptide obesity therapeutics. Metsera's positioning as an emerging oral/injectable obesity player with significant exit value provides a useful precedent for Structure's strategic trajectory.

TypeOthers
Description

Schrödinger is a computational chemistry and molecular simulation company that co-founded Structure Therapeutics and holds ~6% equity. While not a direct therapeutic competitor, Schrödinger's platform powers Structure's structure-based drug design and represents the underlying enabling technology relationship.

TypeRegional player
Description

Innovent is a leading Chinese biopharmaceutical company developing mazdutide, a GLP-1/glucagon dual agonist, primarily for the Chinese market. As a regional obesity player with a multi-mechanism approach, Innovent is comparable to Structure in targeting next-generation obesity mechanisms outside the US/EU.

TypeEmerging player
Description

Keros Therapeutics is a clinical-stage biotech developing therapeutics targeting TGF-beta superfamily and related pathways, with emerging activity in metabolic disease. While focused on different molecular targets, Keros is comparable to Structure as a similarly-sized mid-cap clinical-stage biotech with platform-driven pipeline expansion.

TypeRegional player
Description

Sciwind Biosciences is a Chinese clinical-stage biotech developing oral peptide formulations of semaglutide for the Chinese market. Sciwind's focus on oral GLP-1 obesity therapeutics makes it thematically comparable to Structure's oral approach, though its regional focus limits direct US/EU overlap.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors23 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Structure Therapeutics

Obesity Therapeuticsstructuretx.com

Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for chronic metabolic and cardiopulmonary diseases, anchored by its GLP-1 agonist aleniglipron (Phase 2) for obesity and built on a structure-based drug design platform targeting GPCRs.

What Structure Therapeutics does

Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for chronic metabolic and cardiopulmonary diseases, with an initial focus on obesity. The company was founded in 2016 and is headquartered in South San Francisco, California, with a research and development center in Shanghai, China; it is publicly listed on NASDAQ under the ticker GPCR. Its core technology is a proprietary structure-based drug design platform that combines G-protein-coupled receptor (GPCR) structural biology, computational chemistry, and data science to design oral small molecules against the largest family of drug targets across multiple disease areas.

The company's pipeline is anchored by aleniglipron (also known as GSBR-1290), an oral small molecule GLP-1 receptor agonist that demonstrated up to 16.3% placebo-adjusted weight loss in the Phase 2 ACCESS II trial at 44 weeks with the 180mg dose and an overall discontinuation rate of 10.4%. Phase 3 initiation is planned for Q3 2026 with potential FDA approval targeted by 2029. The pipeline also includes ACCG-2671, an oral small molecule dual amylin and calcitonin receptor agonist in Phase 1; ACCG-3535, a preclinical dual amylin/calcitonin receptor agonist; and earlier-stage GIPR, GCGR, and GLP-1RA + Amylin combination programs. The platform was co-developed within Schrödinger's ecosystem, which retains approximately 6% equity in Structure.

Structure Therapeutics is pre-revenue and currently monetizes only through a non-exclusive patent licensing agreement with Roche/Genentech (CT-996 program) worth $100 million upfront plus low-single-digit royalties. Future revenue is expected to come from the sale of prescription oral obesity and metabolic disease medications upon regulatory approval, distributed through standard pharmaceutical wholesale and specialty pharmacy channels, targeting a global obesity population of more than 800 million patients and a total addressable market exceeding $100 billion. The company carries $1.4–1.5 billion in cash and investments as of early 2026 following a $747.5 million upsized public offering in December 2025, providing runway through 2028.

Structure Therapeutics firmographics

Firmographics
Name
Structure Therapeutics
Legal name
Structure Therapeutics, Inc.
Website
https://structuretx.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
251–500 employees
Short description
Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for chronic metabolic and cardiopulmonary diseases, anchored by its GLP-1 agonist aleniglipron (Phase 2) for obesity and built on a structure-based drug design platform targeting GPCRs.
Ownership category
akta.pro rank

Structure Therapeutics industry classification

Industry
Product category
Obesity Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Oral small molecule therapeutics
  • GPCR drug discovery
  • Obesity treatment pipeline
  • Structure-based drug design
  • Metabolic disease medicines

Where Structure Therapeutics is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Structure Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Pharmaceutical Product Sales: Structure Therapeutics is a pre-revenue clinical-stage biopharmaceutical company. Once products receive regulatory approval, the company plans to generate revenue through the sale of prescription medications, initially targeting the obesity and metabolic disease markets with oral small molecule GLP-1 and amylin receptor agonist therapeutics.

Go-to-market motion1 record

Marketing channels5 records

Structure Therapeutics product offering

Product offering

Core offering

Structure Therapeutics is a clinical-stage biopharmaceutical company that develops oral small molecule therapeutics targeting G-protein-coupled receptors (GPCRs) for chronic metabolic and cardiopulmonary diseases, with an initial focus on obesity. The company leverages a proprietary structure-based drug design platform to create oral, non-peptide alternatives to injectable biologic and peptide therapies, addressing scalability, cost, and administration challenges of current treatments.

Product overview

Structure Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of oral small molecule therapeutics for chronic metabolic and cardiopulmonary diseases, with an initial focus on obesity. The company's portfolio includes Aleniglipron (GSBR-1290), a GLP-1 receptor agonist in Phase 2 development showing up to 16.3% weight loss; ACCG-2671, a dual amylin and calcitonin receptor agonist in Phase 1; and ACCG-3535, a preclinical dual amylin/calcitonin receptor agonist. These candidates are designed as oral alternatives to injectable biologic and peptide therapies, leveraging the company's structure-based drug design platform targeting GPCRs to improve scalability and patient accessibility.

Differentiator

Problem solved

Functional benefit

Brands

  • Aleniglipron: Oral small molecule GLP-1 receptor agonist for obesity treatment, currently in Phase 2 clinical trials showing up to 16.2% weight loss.
  • ACCG-2671
  • ACCG-3535
  • GSBR-1290

Products and services

  • Aleniglipron (GSBR-1290) An oral small molecule GLP-1 receptor agonist (GLP-1RA) for obesity treatment. Demonstrated up to 16.3% placebo-adjusted weight loss in Phase 2b ACCESS trials and positioned as a potential best-in-class oral GLP-1 therapy.
  • ACCG-2671 An oral small molecule dual amylin and calcitonin receptor agonist (DACRA) for obesity treatment. Currently in Phase 1 clinical study evaluating safety, tolerability, and pharmacokinetics in healthy volunteers and individuals with obesity.
  • ACCG-3535 A novel oral small molecule dual amylin and calcitonin receptor agonist for obesity treatment, in preclinical development stage.
  • GIPR Program Discovery-stage oral small molecule program targeting the GIP receptor for obesity and metabolic disease treatment.
  • GCGR Program Discovery-stage oral small molecule program targeting the glucagon receptor for obesity and metabolic disease treatment.
  • GLP-1RA + Amylin Combination Combination therapy program combining an oral GLP-1 receptor agonist with an amylin receptor agonist for obesity treatment, in IND-enabling development.

Quantifiable outcome

  • Up to 16.3% placebo-adjusted weight loss at 44 weeks with aleniglipron 180mg dose in Phase 2 ACCESS II trial
  • +4 more outcomes

Companies that use Structure Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Structure Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Structure Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Roche/GenentechcoreOEM/ Whitelabel/ Licensing Partner · 5 January 2026Structure Therapeutics licensed patents to Roche for CT-996 (oral GLP-1 drug acquired through Carmot Therapeutics for $2.7 billion) in a deal worth $100 million upfront plus additional low-single-digit royalties on future net sales. The agreement protects Roche from potential patent infringement claims related to the drug, with Leerink Partners analysts noting this validates Structure's IP position in the oral GLP-1 space.
  • Schrödinger (Co-founding Entity)coreStrategic or Co-development PartnerStructure Therapeutics was co-founded as part of Schrödinger's ecosystem of co-founded companies. Schrödinger holds approximately 6% equity in Structure and highlighted the company's Phase 2b data as a key milestone in its 2025 business update. Structure's structure-based drug discovery platform benefits from Schrödinger's computational molecular discovery capabilities.

Scale indicators16 records

Recent moves6 records

Expansion highlights6 records

Structure Therapeutics competitors and assessment

Company assessment

Direct peers

  • Terns Pharmaceuticals: Terns Pharmaceuticals is a clinical-stage biotech developing TERN-601, an oral small molecule GLP-1 receptor agonist for obesity. Terns is one of the closest direct competitors to Structure's aleniglipron, targeting the same oral small molecule GLP-1 niche with similar patient access and scalability advantages over injectables.
  • Viking Therapeutics: Viking Therapeutics is a clinical-stage obesity-focused biotech with VK2735 (dual GLP-1/GIP injectable) showing strong weight loss in trials. While Viking's lead is injectable versus Structure's oral approach, both are mid-cap biotechs pursuing differentiated next-generation obesity therapeutics with similar competitive dynamics.

Broad incumbents

  • Eli Lilly: Eli Lilly is the dominant incumbent in the GLP-1 obesity market with orforglipron (oral small molecule GLP-1 in late-stage trials) and retatrutide (28.3% weight loss in Phase 3). Lilly's massive commercial infrastructure, manufacturing scale, and capital make it Structure's most significant competitive threat and benchmark for oral GLP-1 efficacy.
  • Roche/Genentech: Roche/Genentech acquired Carmot Therapeutics for $2.7B to access CT-996, an oral small molecule GLP-1, and subsequently licensed Structure's GLP-1 patents for $100M upfront. Roche is both a strategic counterparty and a competitive oral GLP-1 developer, making it a uniquely adjacent peer.
  • Novo Nordisk: Novo Nordisk pioneered the GLP-1 category with semaglutide (Wegovy/Ozempic) and is advancing oral semaglutide formulations. As the established market leader with deep physician relationships, payer contracts, and global manufacturing, Novo represents both the incumbent benchmark and the most direct threat to Structure's oral obesity positioning.

Emerging players

  • Metsera: Metsera was an emerging obesity biotech (recently acquired by Pfizer for ~$10B) developing next-generation injectable and oral peptide obesity therapeutics. Metsera's positioning as an emerging oral/injectable obesity player with significant exit value provides a useful precedent for Structure's strategic trajectory.
  • Keros Therapeutics: Keros Therapeutics is a clinical-stage biotech developing therapeutics targeting TGF-beta superfamily and related pathways, with emerging activity in metabolic disease. While focused on different molecular targets, Keros is comparable to Structure as a similarly-sized mid-cap clinical-stage biotech with platform-driven pipeline expansion.

Others

  • Schrödinger: Schrödinger is a computational chemistry and molecular simulation company that co-founded Structure Therapeutics and holds ~6% equity. While not a direct therapeutic competitor, Schrödinger's platform powers Structure's structure-based drug design and represents the underlying enabling technology relationship.

Regional players

  • Innovent Biologics: Innovent is a leading Chinese biopharmaceutical company developing mazdutide, a GLP-1/glucagon dual agonist, primarily for the Chinese market. As a regional obesity player with a multi-mechanism approach, Innovent is comparable to Structure in targeting next-generation obesity mechanisms outside the US/EU.
  • Sciwind Biosciences: Sciwind Biosciences is a Chinese clinical-stage biotech developing oral peptide formulations of semaglutide for the Chinese market. Sciwind's focus on oral GLP-1 obesity therapeutics makes it thematically comparable to Structure's oral approach, though its regional focus limits direct US/EU overlap.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Structure Therapeutics social profiles

Digital presence

Structure Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Structure Therapeutics leadership team

Management profile

Number of profiles

Profiles16 records

Structure Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Structure Therapeutics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors23 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Structure Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Structure Therapeutics

What does Structure Therapeutics do?

Structure Therapeutics is a clinical-stage biopharmaceutical company that develops oral small molecule therapeutics targeting G-protein-coupled receptors (GPCRs) for chronic metabolic and cardiopulmonary diseases, with an initial focus on obesity. The company leverages a proprietary structure-based drug design platform to create oral, non-peptide alternatives to injectable biologic and peptide therapies, addressing scalability, cost, and administration challenges of current treatments.

Is Structure Therapeutics a public or private company?

Structure Therapeutics is a public company. It is classified as public and is currently operating.

When was Structure Therapeutics founded?

Structure Therapeutics was founded in 2019. It employs 251 to 500 people.

Where is Structure Therapeutics based?

Structure Therapeutics is headquartered in South San Francisco, United States, in the North America region.

How does Structure Therapeutics make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Structure Therapeutics's main competitors?

Direct peers on record are Terns Pharmaceuticals and Viking Therapeutics. Broad incumbents are Eli Lilly, Roche/Genentech and Novo Nordisk. Emerging players are Metsera and Keros Therapeutics. Schrödinger is listed as an others. Regional players are Innovent Biologics and Sciwind Biosciences.

Does Structure Therapeutics have an API?

No public API is recorded for Structure Therapeutics.

What industry is Structure Therapeutics in?

Structure Therapeutics's product category is Obesity Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comStructure Therapeutics at Jefferies Global Healthcare Conference: oral obesity pushStructure Therapeutics outlined its oral obesity strategy at the Jefferies Global Healthcare Conference, focusing on aleniglipron in Phase III and ACCG-2671, a first-in-class oral amylin agonist in Phase IIa. The company's shares closed at $18.57, down 80% from the 52-week high, and no financial results were disclosed.Investing.comStructure Therapeutics stock hits 52-week low at $18.68Structure Therapeutics ADR hit a 52-week low of $18.68, down 49.52% over the past year and 71% year-to-date. Analysts maintain Buy ratings with price targets from $70 to $145, citing promising trial data from ACCG-2671 and aleniglipron.Simply Wall StStructure Therapeutics (GPCR) After Wider Q3 Losses Still Screens Cheap On Obesity Trial PromiseStructure Therapeutics reported a Q3 loss of $144.76 million, driven by spending on two Phase 3 obesity trials. Its share price fell 61.57% over 90 days, though the company holds $1.4 billion in net cash. Analysts see a fair value of $105.78, citing potential revenue from aleniglipron.The future of tradingStructure Therapeutics Inc. <gpcr.oq> expected to post a loss of 59 cents a share - Earnings PreviewStructure Therapeutics is expected to report a loss of 59 cents per share on November 11, with no change in quarterly revenue. Analysts rate the stock a buy, with 16 buy or strong buy ratings and a median price target of $110, about 440% above the last closing price.Stock TitanStructure Therapeutics Q3 net loss widens to $145MStructure Therapeutics reported a Q3 2026 net loss of $144.8 million, up from $65.7 million in 2025, with R&D expenses rising to $134.6 million. The company held $1.2 billion in cash and expects to fund operations through 2028. Aleniglipron Phase 3 trials are underway, with topline data expected in 2028.GlobeNewswireStructure Therapeutics Reports Third Quarter 2026 Financial Results and Recent HighlightsStructure Therapeutics reported Q3 2026 financial results, with a net loss of $144.8 million and $1.2 billion in cash as of September 30, 2026. The company's Phase 3 ACCOMPLISH trials for aleniglipron are underway, with topline data expected in H2 2028, and additional aleniglipron data in Q4 2026.Business & FinancialStructure Therapeutics Reports Third Quarter 2026 Financial Results And Recent HighlightsStructure Therapeutics reported Q3 2026 financial results, with a net loss of $144.8 million and $1.2 billion in cash. The company highlighted Phase 3 ACCOMPLISH trials for aleniglipron and Phase 1 data for ACCG-2671, with topline data expected in 2027-2028.FinancialContent Business PageStructure Therapeutics to Participate in the Jefferies Global Healthcare ConferenceStructure Therapeutics management will participate in the Jefferies Global Healthcare Conference on November 17, 2026, in London. The company, developing oral small molecule therapeutics for metabolic diseases, will hold a fireside chat and 1x1 meetings. Webcasts will be available on the company's website for at least 90 days.Stock TitanStructure Therapeutics to Join Jefferies ConferenceStructure Therapeutics management will participate in the Jefferies Global Healthcare Conference in London on November 17, 2026. The company, developing oral small molecule therapeutics for metabolic diseases, will hold a fireside chat and 1x1 meetings. Webcasts will be available on the company's website for at least 90 days.GlobeNewswireStructure Therapeutics to Participate in the Jefferies Global Healthcare ConferenceStructure Therapeutics management will participate in the Jefferies Global Healthcare Conference on November 17, 2026, in London. The company, developing oral small molecule therapeutics for metabolic diseases, will hold a fireside chat and 1x1 meetings. Webcasts will be available for at least 90 days.